Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aortic Valve | 51 | 2023 | 428 | 8.540 |
Why?
|
Aortic Valve Stenosis | 42 | 2023 | 315 | 7.370 |
Why?
|
Calcinosis | 27 | 2022 | 292 | 4.140 |
Why?
|
Toll-Like Receptor 4 | 35 | 2021 | 335 | 4.100 |
Why?
|
Thoracic Surgery | 14 | 2020 | 123 | 2.940 |
Why?
|
Osteogenesis | 21 | 2022 | 222 | 2.920 |
Why?
|
Cardiac Surgical Procedures | 22 | 2020 | 477 | 2.850 |
Why?
|
Spinal Cord Ischemia | 17 | 2022 | 79 | 2.280 |
Why?
|
Reperfusion Injury | 20 | 2022 | 279 | 2.210 |
Why?
|
Vasodilation | 24 | 1999 | 462 | 2.090 |
Why?
|
Pulmonary Artery | 31 | 2011 | 1097 | 1.870 |
Why?
|
Endotoxins | 17 | 2010 | 234 | 1.630 |
Why?
|
Certification | 5 | 2019 | 110 | 1.550 |
Why?
|
Cardiopulmonary Bypass | 14 | 2019 | 213 | 1.520 |
Why?
|
Lung Transplantation | 16 | 2023 | 273 | 1.490 |
Why?
|
Up-Regulation | 17 | 2020 | 891 | 1.460 |
Why?
|
Simvastatin | 5 | 2022 | 68 | 1.450 |
Why?
|
NF-kappa B | 23 | 2022 | 676 | 1.440 |
Why?
|
Heart Valve Diseases | 14 | 2020 | 137 | 1.430 |
Why?
|
Cells, Cultured | 43 | 2023 | 4162 | 1.400 |
Why?
|
Toll-Like Receptor 2 | 12 | 2022 | 131 | 1.380 |
Why?
|
Cyclic GMP | 23 | 1999 | 111 | 1.380 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 410 | 1.370 |
Why?
|
Bone Morphogenetic Protein 2 | 15 | 2018 | 94 | 1.360 |
Why?
|
Muscle, Smooth, Vascular | 19 | 1998 | 454 | 1.330 |
Why?
|
Heart Transplantation | 18 | 2023 | 674 | 1.280 |
Why?
|
Esophageal Neoplasms | 12 | 2022 | 287 | 1.220 |
Why?
|
Pulmonary Circulation | 13 | 1999 | 455 | 1.150 |
Why?
|
Intercellular Adhesion Molecule-1 | 16 | 2022 | 177 | 1.140 |
Why?
|
Heart Valve Prosthesis Implantation | 12 | 2016 | 191 | 1.090 |
Why?
|
Core Binding Factor Alpha 1 Subunit | 8 | 2023 | 52 | 1.050 |
Why?
|
Postoperative Complications | 20 | 2020 | 2301 | 0.980 |
Why?
|
Adenocarcinoma | 13 | 2022 | 837 | 0.970 |
Why?
|
Vasomotor System | 8 | 1997 | 49 | 0.950 |
Why?
|
Aorta, Thoracic | 14 | 2022 | 252 | 0.930 |
Why?
|
Erythropoietin | 7 | 2018 | 82 | 0.930 |
Why?
|
Thoracic Surgical Procedures | 3 | 2019 | 65 | 0.920 |
Why?
|
Lipoproteins, LDL | 6 | 2017 | 138 | 0.920 |
Why?
|
Humans | 191 | 2023 | 122796 | 0.900 |
Why?
|
Specialty Boards | 3 | 2019 | 43 | 0.900 |
Why?
|
Vasodilator Agents | 13 | 2018 | 339 | 0.890 |
Why?
|
Spinal Cord | 10 | 2018 | 364 | 0.850 |
Why?
|
Male | 150 | 2022 | 59639 | 0.850 |
Why?
|
Signal Transduction | 38 | 2023 | 4902 | 0.840 |
Why?
|
Tissue and Organ Procurement | 6 | 2023 | 243 | 0.820 |
Why?
|
Phospholipases A2, Secretory | 7 | 2019 | 27 | 0.820 |
Why?
|
Inflammation | 10 | 2021 | 2598 | 0.820 |
Why?
|
Myocardium | 15 | 2017 | 982 | 0.810 |
Why?
|
Lipopolysaccharides | 15 | 2020 | 875 | 0.810 |
Why?
|
Group II Phospholipases A2 | 6 | 2020 | 23 | 0.790 |
Why?
|
Clinical Competence | 9 | 2020 | 973 | 0.790 |
Why?
|
Coronary Artery Bypass | 9 | 2021 | 226 | 0.770 |
Why?
|
Nitric Oxide | 13 | 2021 | 884 | 0.770 |
Why?
|
Endothelium, Vascular | 17 | 2017 | 923 | 0.750 |
Why?
|
Diazoxide | 5 | 2021 | 32 | 0.740 |
Why?
|
Middle Aged | 70 | 2022 | 28563 | 0.730 |
Why?
|
Paraplegia | 9 | 2022 | 63 | 0.730 |
Why?
|
Lung | 20 | 2011 | 3830 | 0.720 |
Why?
|
Rats, Sprague-Dawley | 36 | 2012 | 2501 | 0.710 |
Why?
|
Nitroprusside | 22 | 1999 | 90 | 0.710 |
Why?
|
Pulmonary Valve | 8 | 2015 | 101 | 0.710 |
Why?
|
Animals | 99 | 2023 | 34133 | 0.700 |
Why?
|
Vascular Resistance | 15 | 2011 | 374 | 0.700 |
Why?
|
Organ Transplantation | 1 | 2021 | 165 | 0.690 |
Why?
|
Myocardial Ischemia | 8 | 2011 | 267 | 0.690 |
Why?
|
Heart Diseases | 6 | 2022 | 358 | 0.680 |
Why?
|
Wnt Signaling Pathway | 1 | 2020 | 153 | 0.680 |
Why?
|
Extracellular Matrix Proteins | 3 | 2021 | 133 | 0.670 |
Why?
|
Gastroesophageal Reflux | 6 | 2022 | 252 | 0.660 |
Why?
|
Education, Medical, Graduate | 4 | 2019 | 432 | 0.660 |
Why?
|
Social Responsibility | 1 | 2019 | 51 | 0.660 |
Why?
|
Spinal Cord Injuries | 5 | 2021 | 184 | 0.650 |
Why?
|
Cardiac Catheterization | 9 | 2016 | 577 | 0.650 |
Why?
|
Neutrophils | 14 | 2011 | 1246 | 0.630 |
Why?
|
Interleukin-6 | 6 | 2022 | 702 | 0.630 |
Why?
|
Cyclic AMP | 11 | 1997 | 260 | 0.620 |
Why?
|
Barrett Esophagus | 5 | 2022 | 159 | 0.620 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 5 | 2020 | 179 | 0.610 |
Why?
|
Vasoconstriction | 9 | 1999 | 216 | 0.610 |
Why?
|
Receptors, Erythropoietin | 4 | 2018 | 25 | 0.610 |
Why?
|
Coronary Vessels | 5 | 2021 | 237 | 0.600 |
Why?
|
Hypertension, Pulmonary | 13 | 1998 | 1900 | 0.590 |
Why?
|
Inflammation Mediators | 5 | 2022 | 515 | 0.590 |
Why?
|
Surgical Wound Infection | 3 | 2014 | 251 | 0.580 |
Why?
|
Time Factors | 34 | 2019 | 6682 | 0.580 |
Why?
|
Rats | 36 | 2012 | 5426 | 0.570 |
Why?
|
Adenosine | 6 | 1997 | 212 | 0.570 |
Why?
|
Health Resources | 1 | 2017 | 136 | 0.570 |
Why?
|
Acetylcholine | 18 | 1999 | 211 | 0.560 |
Why?
|
Myocardial Reperfusion Injury | 6 | 2015 | 107 | 0.550 |
Why?
|
Lung Neoplasms | 10 | 2019 | 2216 | 0.550 |
Why?
|
Myocardial Revascularization | 3 | 2001 | 84 | 0.540 |
Why?
|
Aortic Aneurysm, Thoracic | 5 | 2022 | 124 | 0.540 |
Why?
|
Mice, Inbred C57BL | 31 | 2022 | 5020 | 0.540 |
Why?
|
Cardiology | 7 | 2020 | 338 | 0.530 |
Why?
|
Mitral Valve | 6 | 2014 | 94 | 0.530 |
Why?
|
Enzyme Inhibitors | 9 | 2020 | 836 | 0.530 |
Why?
|
Endotoxemia | 6 | 2017 | 93 | 0.530 |
Why?
|
Transcatheter Aortic Valve Replacement | 4 | 2022 | 162 | 0.520 |
Why?
|
Calcium-Binding Proteins | 3 | 2015 | 222 | 0.520 |
Why?
|
Aged | 47 | 2021 | 20495 | 0.510 |
Why?
|
Adult | 43 | 2023 | 32385 | 0.510 |
Why?
|
Down-Regulation | 7 | 2020 | 654 | 0.500 |
Why?
|
Laser Therapy | 3 | 2001 | 105 | 0.500 |
Why?
|
Monocytes | 3 | 2022 | 523 | 0.490 |
Why?
|
Postoperative Care | 4 | 2011 | 245 | 0.490 |
Why?
|
Cell Proliferation | 12 | 2020 | 2328 | 0.490 |
Why?
|
Blood Vessel Prosthesis Implantation | 3 | 2022 | 187 | 0.480 |
Why?
|
Dexmedetomidine | 5 | 2014 | 58 | 0.480 |
Why?
|
United States | 24 | 2023 | 13272 | 0.480 |
Why?
|
Mice | 45 | 2023 | 15888 | 0.480 |
Why?
|
Glucuronidase | 3 | 2020 | 49 | 0.480 |
Why?
|
Interleukin-1 | 6 | 2023 | 987 | 0.480 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 5 | 2021 | 159 | 0.480 |
Why?
|
Sodium-Phosphate Cotransporter Proteins, Type III | 1 | 2013 | 6 | 0.470 |
Why?
|
Tumor Necrosis Factor-alpha | 12 | 2013 | 1181 | 0.470 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 4 | 2014 | 31 | 0.470 |
Why?
|
Calcium Phosphates | 1 | 2013 | 26 | 0.460 |
Why?
|
Osteopontin | 2 | 2012 | 39 | 0.460 |
Why?
|
Guideline Adherence | 2 | 2014 | 560 | 0.460 |
Why?
|
Neuroprotective Agents | 4 | 2018 | 110 | 0.460 |
Why?
|
Interleukin-1beta | 2 | 2013 | 383 | 0.450 |
Why?
|
Hospital Mortality | 9 | 2020 | 901 | 0.450 |
Why?
|
Aging | 5 | 2022 | 1694 | 0.450 |
Why?
|
STAT3 Transcription Factor | 5 | 2019 | 193 | 0.450 |
Why?
|
Myofibroblasts | 4 | 2018 | 132 | 0.450 |
Why?
|
Salmonella typhimurium | 6 | 2000 | 179 | 0.430 |
Why?
|
Alkaline Phosphatase | 7 | 2019 | 161 | 0.430 |
Why?
|
Heart | 11 | 2023 | 649 | 0.420 |
Why?
|
Proto-Oncogene Proteins c-akt | 8 | 2020 | 433 | 0.420 |
Why?
|
Quality Assurance, Health Care | 1 | 2014 | 362 | 0.420 |
Why?
|
Disease Models, Animal | 22 | 2022 | 3799 | 0.420 |
Why?
|
Hemodynamics | 11 | 2003 | 1036 | 0.410 |
Why?
|
Esophagus | 5 | 2020 | 243 | 0.410 |
Why?
|
Ischemia | 6 | 2022 | 382 | 0.400 |
Why?
|
Biglycan | 4 | 2017 | 11 | 0.400 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 8 | 2017 | 839 | 0.400 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2020 | 249 | 0.400 |
Why?
|
Radiation Injuries | 1 | 2012 | 137 | 0.400 |
Why?
|
Cardiovascular Surgical Procedures | 3 | 2020 | 38 | 0.400 |
Why?
|
Neovascularization, Physiologic | 3 | 2002 | 192 | 0.400 |
Why?
|
Chemokines | 5 | 2015 | 233 | 0.390 |
Why?
|
Societies, Medical | 6 | 2020 | 741 | 0.390 |
Why?
|
Phenotype | 10 | 2017 | 3070 | 0.390 |
Why?
|
Smad1 Protein | 2 | 2014 | 20 | 0.390 |
Why?
|
Receptors, Adrenergic, beta | 6 | 1997 | 146 | 0.390 |
Why?
|
Heme Oxygenase-1 | 2 | 2009 | 52 | 0.390 |
Why?
|
Interleukins | 3 | 2022 | 246 | 0.390 |
Why?
|
Hyperglycemia | 1 | 2014 | 326 | 0.390 |
Why?
|
Oxygen | 4 | 2008 | 887 | 0.390 |
Why?
|
Chemokine CCL2 | 5 | 2017 | 126 | 0.390 |
Why?
|
Specialties, Surgical | 1 | 2011 | 76 | 0.380 |
Why?
|
Recombinant Proteins | 12 | 2023 | 1318 | 0.380 |
Why?
|
Pneumonectomy | 3 | 2019 | 123 | 0.380 |
Why?
|
In Vitro Techniques | 14 | 2009 | 1130 | 0.380 |
Why?
|
Female | 69 | 2022 | 63629 | 0.380 |
Why?
|
Peroxidase | 9 | 1999 | 182 | 0.370 |
Why?
|
Intensive Care Units | 3 | 2020 | 664 | 0.360 |
Why?
|
Intraoperative Complications | 3 | 1996 | 132 | 0.360 |
Why?
|
Myeloid Differentiation Factor 88 | 3 | 2020 | 99 | 0.360 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2011 | 256 | 0.360 |
Why?
|
Circulatory Arrest, Deep Hypothermia Induced | 2 | 2020 | 19 | 0.360 |
Why?
|
Internship and Residency | 7 | 2020 | 1065 | 0.360 |
Why?
|
Thoracotomy | 4 | 2019 | 86 | 0.350 |
Why?
|
Isoproterenol | 11 | 1998 | 127 | 0.340 |
Why?
|
Treatment Outcome | 22 | 2022 | 9692 | 0.340 |
Why?
|
Arginine | 4 | 1999 | 254 | 0.340 |
Why?
|
Receptor, Notch1 | 3 | 2014 | 65 | 0.340 |
Why?
|
Myocardial Contraction | 9 | 2008 | 339 | 0.340 |
Why?
|
Neurotrophin 3 | 2 | 2020 | 16 | 0.340 |
Why?
|
Matrilin Proteins | 4 | 2022 | 17 | 0.330 |
Why?
|
Phosphodiesterase Inhibitors | 3 | 1997 | 90 | 0.330 |
Why?
|
Microglia | 4 | 2013 | 214 | 0.320 |
Why?
|
Cardiac Tamponade | 1 | 2008 | 16 | 0.320 |
Why?
|
Veins | 2 | 2008 | 63 | 0.320 |
Why?
|
Gene Expression Regulation | 6 | 2021 | 2491 | 0.320 |
Why?
|
Calcimycin | 9 | 1999 | 58 | 0.320 |
Why?
|
Oxyhemoglobins | 1 | 2007 | 19 | 0.310 |
Why?
|
Triage | 2 | 2020 | 215 | 0.310 |
Why?
|
Retrospective Studies | 25 | 2023 | 13433 | 0.310 |
Why?
|
Blood Substitutes | 1 | 2007 | 16 | 0.310 |
Why?
|
Kupffer Cells | 1 | 2007 | 48 | 0.310 |
Why?
|
Lung Injury | 5 | 1999 | 215 | 0.300 |
Why?
|
Esophagitis, Peptic | 2 | 2022 | 17 | 0.300 |
Why?
|
Cytokines | 11 | 2017 | 1928 | 0.300 |
Why?
|
Thoracic Injuries | 1 | 2008 | 64 | 0.300 |
Why?
|
Bacterial Toxins | 2 | 1998 | 107 | 0.300 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 1055 | 0.290 |
Why?
|
Troponin I | 2 | 2013 | 83 | 0.290 |
Why?
|
Genetic Therapy | 2 | 2012 | 265 | 0.290 |
Why?
|
Receptors, Purinergic P1 | 2 | 1997 | 26 | 0.290 |
Why?
|
Transforming Growth Factor beta1 | 3 | 2017 | 169 | 0.290 |
Why?
|
Biomarkers | 11 | 2022 | 3662 | 0.290 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2020 | 1981 | 0.280 |
Why?
|
Apoptosis | 6 | 2018 | 2532 | 0.280 |
Why?
|
Hypothermia, Induced | 2 | 2005 | 69 | 0.280 |
Why?
|
Insulin | 2 | 2023 | 2180 | 0.280 |
Why?
|
Aorta | 4 | 2015 | 368 | 0.280 |
Why?
|
Heart Defects, Congenital | 7 | 2020 | 721 | 0.280 |
Why?
|
Coronary Artery Disease | 3 | 2021 | 695 | 0.270 |
Why?
|
Survival Rate | 11 | 2023 | 1810 | 0.270 |
Why?
|
Wounds, Nonpenetrating | 2 | 2008 | 290 | 0.270 |
Why?
|
Mitral Valve Stenosis | 2 | 1996 | 21 | 0.270 |
Why?
|
Case-Control Studies | 9 | 2022 | 3296 | 0.270 |
Why?
|
Matrix Metalloproteinases | 2 | 2017 | 91 | 0.260 |
Why?
|
Acute Kidney Injury | 4 | 2020 | 755 | 0.260 |
Why?
|
Blood Glucose | 1 | 2014 | 1957 | 0.260 |
Why?
|
Immunity, Innate | 2 | 2008 | 762 | 0.260 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 361 | 0.260 |
Why?
|
Vascular Calcification | 2 | 2017 | 124 | 0.260 |
Why?
|
Blotting, Western | 9 | 2021 | 1225 | 0.260 |
Why?
|
Echocardiography, Transesophageal | 3 | 2009 | 92 | 0.260 |
Why?
|
Collagen | 4 | 2022 | 436 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 967 | 0.250 |
Why?
|
Analysis of Variance | 11 | 2019 | 1329 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 349 | 0.250 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 1519 | 0.250 |
Why?
|
Muscle Relaxation | 4 | 1997 | 32 | 0.250 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 5 | 2018 | 290 | 0.250 |
Why?
|
Heart Arrest, Induced | 2 | 2003 | 32 | 0.250 |
Why?
|
Ventricular Function, Left | 2 | 2017 | 493 | 0.250 |
Why?
|
Patient Care Team | 5 | 2014 | 520 | 0.240 |
Why?
|
Heart Ventricles | 5 | 2017 | 741 | 0.240 |
Why?
|
Imaging, Three-Dimensional | 2 | 2019 | 511 | 0.240 |
Why?
|
Pandemics | 3 | 2021 | 1401 | 0.240 |
Why?
|
Drug Evaluation, Preclinical | 4 | 2020 | 187 | 0.240 |
Why?
|
HSP27 Heat-Shock Proteins | 3 | 2014 | 14 | 0.240 |
Why?
|
Perfusion | 3 | 2014 | 160 | 0.240 |
Why?
|
Propensity Score | 3 | 2019 | 253 | 0.240 |
Why?
|
Organ Preservation Solutions | 1 | 2023 | 44 | 0.240 |
Why?
|
Endothelial Cells | 4 | 2021 | 749 | 0.240 |
Why?
|
Receptors, Adrenergic, alpha-2 | 2 | 2013 | 17 | 0.230 |
Why?
|
Primary Graft Dysfunction | 1 | 2023 | 32 | 0.230 |
Why?
|
Cardiomyopathy, Dilated | 2 | 2018 | 349 | 0.230 |
Why?
|
Lipopeptides | 2 | 2020 | 16 | 0.230 |
Why?
|
Tissue Donors | 5 | 2023 | 337 | 0.230 |
Why?
|
Respiration | 2 | 1995 | 189 | 0.230 |
Why?
|
Osteoblasts | 3 | 2017 | 119 | 0.230 |
Why?
|
Aortic Valve Insufficiency | 1 | 2003 | 45 | 0.230 |
Why?
|
MicroRNAs | 3 | 2019 | 661 | 0.230 |
Why?
|
Vena Cava, Inferior | 1 | 2003 | 56 | 0.230 |
Why?
|
Immunoblotting | 5 | 2017 | 318 | 0.230 |
Why?
|
Primary Cell Culture | 3 | 2018 | 156 | 0.230 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 1003 | 0.230 |
Why?
|
HIV Infections | 1 | 2017 | 2532 | 0.230 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2003 | 64 | 0.230 |
Why?
|
RNA Interference | 6 | 2017 | 473 | 0.230 |
Why?
|
Educational Measurement | 5 | 2019 | 298 | 0.230 |
Why?
|
Osteosarcoma | 1 | 2003 | 70 | 0.220 |
Why?
|
Anti-Inflammatory Agents | 4 | 2023 | 469 | 0.220 |
Why?
|
Neoplasm Proteins | 3 | 2019 | 415 | 0.220 |
Why?
|
Interleukin-8 | 3 | 2008 | 256 | 0.220 |
Why?
|
Anti-Arrhythmia Agents | 2 | 2013 | 132 | 0.220 |
Why?
|
Immunohistochemistry | 6 | 2012 | 1727 | 0.220 |
Why?
|
Vinblastine | 3 | 1996 | 69 | 0.210 |
Why?
|
Coronary Circulation | 4 | 1999 | 121 | 0.210 |
Why?
|
Adaptor Proteins, Vesicular Transport | 2 | 2019 | 49 | 0.210 |
Why?
|
Phosphorylation | 10 | 2018 | 1733 | 0.210 |
Why?
|
Cohort Studies | 6 | 2021 | 5294 | 0.210 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 91 | 0.210 |
Why?
|
Lung Diseases | 3 | 2008 | 764 | 0.210 |
Why?
|
Cell Culture Techniques | 3 | 2019 | 354 | 0.210 |
Why?
|
beta Catenin | 2 | 2021 | 223 | 0.210 |
Why?
|
Ultrasonic Therapy | 1 | 2001 | 12 | 0.210 |
Why?
|
Patient Readmission | 2 | 2018 | 691 | 0.210 |
Why?
|
Tumor Burden | 2 | 2020 | 277 | 0.200 |
Why?
|
Technology Transfer | 1 | 2021 | 14 | 0.200 |
Why?
|
Electrosurgery | 1 | 2001 | 45 | 0.200 |
Why?
|
Bone Neoplasms | 1 | 2003 | 197 | 0.200 |
Why?
|
Pentanoic Acids | 1 | 2020 | 3 | 0.200 |
Why?
|
Potassium Channels | 2 | 2021 | 137 | 0.200 |
Why?
|
Receptor, trkA | 2 | 2020 | 21 | 0.200 |
Why?
|
Heart-Assist Devices | 4 | 2017 | 487 | 0.200 |
Why?
|
Patient Selection | 3 | 2020 | 717 | 0.200 |
Why?
|
Vascular Grafting | 1 | 2020 | 13 | 0.190 |
Why?
|
Length of Stay | 8 | 2020 | 1077 | 0.190 |
Why?
|
Cell Line, Tumor | 10 | 2020 | 2904 | 0.190 |
Why?
|
Disease Susceptibility | 2 | 2022 | 343 | 0.190 |
Why?
|
Risk Factors | 13 | 2019 | 9381 | 0.190 |
Why?
|
Myocarditis | 3 | 2011 | 95 | 0.190 |
Why?
|
Warfarin | 1 | 2021 | 147 | 0.180 |
Why?
|
Catheterization | 2 | 2018 | 165 | 0.180 |
Why?
|
Shock, Cardiogenic | 1 | 2020 | 62 | 0.180 |
Why?
|
Intraoperative Neurophysiological Monitoring | 1 | 2020 | 15 | 0.180 |
Why?
|
Phenylephrine | 5 | 1999 | 85 | 0.180 |
Why?
|
Aortography | 2 | 2019 | 55 | 0.180 |
Why?
|
Receptors, Cell Surface | 2 | 2004 | 368 | 0.180 |
Why?
|
Curriculum | 5 | 2016 | 925 | 0.180 |
Why?
|
Waiting Lists | 1 | 2021 | 229 | 0.180 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2017 | 232 | 0.180 |
Why?
|
Sternum | 3 | 2006 | 17 | 0.180 |
Why?
|
Aspergillosis, Allergic Bronchopulmonary | 1 | 1999 | 10 | 0.180 |
Why?
|
Peptidoglycan | 2 | 2011 | 28 | 0.180 |
Why?
|
Endothelial Growth Factors | 1 | 1999 | 55 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2012 | 622 | 0.180 |
Why?
|
Heart Valve Prosthesis | 3 | 2016 | 126 | 0.180 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2019 | 41 | 0.180 |
Why?
|
Neutropenia | 2 | 1997 | 134 | 0.180 |
Why?
|
Lymphokines | 1 | 1999 | 132 | 0.180 |
Why?
|
Mice, Inbred C3H | 6 | 2021 | 256 | 0.170 |
Why?
|
Hospitals | 2 | 2014 | 633 | 0.170 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2019 | 58 | 0.170 |
Why?
|
HSC70 Heat-Shock Proteins | 2 | 2009 | 6 | 0.170 |
Why?
|
Salmonella typhi | 1 | 1998 | 12 | 0.170 |
Why?
|
Matrix Metalloproteinase 12 | 1 | 2018 | 8 | 0.170 |
Why?
|
Atrioventricular Block | 1 | 2019 | 35 | 0.170 |
Why?
|
Toll-Like Receptor 3 | 2 | 2017 | 32 | 0.170 |
Why?
|
Abscess | 1 | 1999 | 74 | 0.170 |
Why?
|
Atrial Fibrillation | 2 | 2013 | 392 | 0.170 |
Why?
|
Graft Rejection | 8 | 2023 | 556 | 0.170 |
Why?
|
Reactive Oxygen Species | 2 | 2020 | 592 | 0.170 |
Why?
|
Coronary Disease | 2 | 1998 | 372 | 0.170 |
Why?
|
Gene Knockdown Techniques | 3 | 2017 | 322 | 0.170 |
Why?
|
Nerve Growth Factor | 1 | 2018 | 28 | 0.170 |
Why?
|
Cell Movement | 2 | 2014 | 929 | 0.160 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 79 | 0.160 |
Why?
|
Fluorescent Antibody Technique | 6 | 2010 | 420 | 0.160 |
Why?
|
Macrophages | 5 | 2012 | 1334 | 0.160 |
Why?
|
Pneumococcal Infections | 1 | 1999 | 99 | 0.160 |
Why?
|
Carbon Dioxide | 4 | 2005 | 237 | 0.160 |
Why?
|
Receptors, Adrenergic, alpha | 2 | 2000 | 33 | 0.160 |
Why?
|
Dinoprostone | 1 | 2019 | 193 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 1183 | 0.160 |
Why?
|
Creatinine | 1 | 2020 | 510 | 0.160 |
Why?
|
Fibrosis | 1 | 2020 | 497 | 0.160 |
Why?
|
Rwanda | 1 | 2017 | 10 | 0.160 |
Why?
|
Acid-Base Equilibrium | 3 | 2005 | 32 | 0.160 |
Why?
|
Ventricular Function, Right | 2 | 2017 | 262 | 0.160 |
Why?
|
CREB-Binding Protein | 2 | 2014 | 29 | 0.160 |
Why?
|
Swine | 4 | 2002 | 777 | 0.160 |
Why?
|
Pentoxifylline | 1 | 1997 | 21 | 0.160 |
Why?
|
Thrombocytopenia | 1 | 2019 | 188 | 0.160 |
Why?
|
Warm Ischemia | 2 | 2022 | 13 | 0.160 |
Why?
|
Blood Vessel Prosthesis | 4 | 2022 | 119 | 0.160 |
Why?
|
Neuroprotection | 1 | 2017 | 31 | 0.160 |
Why?
|
ADAMTS5 Protein | 1 | 2017 | 7 | 0.150 |
Why?
|
Prosthesis Design | 1 | 2019 | 293 | 0.150 |
Why?
|
Thoracoscopy | 1 | 2017 | 59 | 0.150 |
Why?
|
Pulmonary Edema | 2 | 2011 | 141 | 0.150 |
Why?
|
Nicorandil | 3 | 2021 | 16 | 0.150 |
Why?
|
SOX9 Transcription Factor | 1 | 2017 | 24 | 0.150 |
Why?
|
Cell Transdifferentiation | 1 | 2017 | 32 | 0.150 |
Why?
|
Dipyridamole | 1 | 1997 | 27 | 0.150 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2013 | 334 | 0.150 |
Why?
|
Prospective Studies | 7 | 2020 | 6704 | 0.150 |
Why?
|
Heart Aneurysm | 2 | 1996 | 10 | 0.150 |
Why?
|
Cyclin D1 | 1 | 2017 | 63 | 0.150 |
Why?
|
Splanchnic Circulation | 1 | 1996 | 12 | 0.150 |
Why?
|
Esophagectomy | 1 | 2018 | 112 | 0.150 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 1855 | 0.150 |
Why?
|
Lysophosphatidylcholines | 1 | 2017 | 36 | 0.150 |
Why?
|
Frailty | 1 | 2019 | 117 | 0.150 |
Why?
|
RNA, Double-Stranded | 1 | 2017 | 52 | 0.150 |
Why?
|
Betacoronavirus | 1 | 2020 | 265 | 0.150 |
Why?
|
Stroke | 3 | 2020 | 1090 | 0.140 |
Why?
|
Reperfusion | 1 | 1996 | 45 | 0.140 |
Why?
|
Cell Survival | 6 | 2017 | 1075 | 0.140 |
Why?
|
Blood Pressure | 8 | 1998 | 1713 | 0.140 |
Why?
|
Mesentery | 1 | 1996 | 57 | 0.140 |
Why?
|
Acid-Base Imbalance | 1 | 1996 | 6 | 0.140 |
Why?
|
Multidetector Computed Tomography | 1 | 2016 | 28 | 0.140 |
Why?
|
Premedication | 2 | 1997 | 41 | 0.140 |
Why?
|
Intraoperative Care | 1 | 1996 | 40 | 0.140 |
Why?
|
Phosphates | 1 | 2017 | 170 | 0.140 |
Why?
|
Epigenesis, Genetic | 2 | 2017 | 551 | 0.140 |
Why?
|
Coronary Sinus | 1 | 2015 | 9 | 0.140 |
Why?
|
Prognosis | 6 | 2020 | 3563 | 0.140 |
Why?
|
Heat-Shock Proteins | 3 | 2014 | 129 | 0.140 |
Why?
|
Magnesium | 1 | 1996 | 156 | 0.140 |
Why?
|
Biomarkers, Tumor | 2 | 2020 | 1076 | 0.140 |
Why?
|
Models, Cardiovascular | 3 | 2012 | 183 | 0.140 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2020 | 1265 | 0.130 |
Why?
|
Computed Tomography Angiography | 1 | 2016 | 85 | 0.130 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 1995 | 10 | 0.130 |
Why?
|
Radiography, Interventional | 1 | 2016 | 117 | 0.130 |
Why?
|
Internal Mammary-Coronary Artery Anastomosis | 1 | 1994 | 4 | 0.130 |
Why?
|
Extracellular Space | 3 | 2010 | 132 | 0.130 |
Why?
|
Mucous Membrane | 3 | 2010 | 120 | 0.130 |
Why?
|
Pulmonary Valve Stenosis | 1 | 2015 | 18 | 0.130 |
Why?
|
Acute Disease | 6 | 2011 | 984 | 0.130 |
Why?
|
Transfection | 5 | 2017 | 909 | 0.130 |
Why?
|
Sirolimus | 1 | 2016 | 198 | 0.130 |
Why?
|
Registries | 2 | 2021 | 2020 | 0.130 |
Why?
|
Percutaneous Coronary Intervention | 1 | 2021 | 535 | 0.130 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 2015 | 36 | 0.130 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 2017 | 74 | 0.130 |
Why?
|
Databases, Factual | 5 | 2020 | 1287 | 0.130 |
Why?
|
Accreditation | 1 | 2015 | 96 | 0.130 |
Why?
|
Mitochondria | 1 | 2020 | 809 | 0.130 |
Why?
|
Asphyxia | 1 | 2014 | 23 | 0.130 |
Why?
|
Hypoxia | 3 | 2014 | 1003 | 0.120 |
Why?
|
Administration, Inhalation | 5 | 2012 | 664 | 0.120 |
Why?
|
Risk Assessment | 6 | 2020 | 3213 | 0.120 |
Why?
|
Computer-Assisted Instruction | 2 | 2005 | 67 | 0.120 |
Why?
|
Dogs | 5 | 1996 | 382 | 0.120 |
Why?
|
History, 20th Century | 1 | 2015 | 288 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 3 | 2002 | 3264 | 0.120 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 519 | 0.120 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 1995 | 122 | 0.120 |
Why?
|
Aortic Diseases | 1 | 2015 | 95 | 0.120 |
Why?
|
Health Facilities | 1 | 2014 | 78 | 0.120 |
Why?
|
Mesenteric Vascular Occlusion | 1 | 1993 | 4 | 0.120 |
Why?
|
Drug Costs | 1 | 2014 | 100 | 0.120 |
Why?
|
Motor Activity | 3 | 2014 | 679 | 0.120 |
Why?
|
Microtubules | 1 | 1996 | 247 | 0.120 |
Why?
|
Microfilament Proteins | 1 | 2014 | 135 | 0.120 |
Why?
|
Pancreatic Neoplasms | 2 | 2012 | 803 | 0.120 |
Why?
|
Deglutition Disorders | 1 | 1995 | 135 | 0.120 |
Why?
|
Duodenogastric Reflux | 2 | 2010 | 4 | 0.120 |
Why?
|
Organ Preservation | 3 | 2023 | 67 | 0.120 |
Why?
|
Foscarnet | 1 | 2013 | 19 | 0.120 |
Why?
|
Arterial Occlusive Diseases | 1 | 2014 | 81 | 0.120 |
Why?
|
Autophagy | 1 | 2017 | 321 | 0.120 |
Why?
|
Dimaprit | 3 | 1998 | 6 | 0.120 |
Why?
|
Nitric Oxide Synthase | 3 | 2000 | 227 | 0.120 |
Why?
|
Reoperation | 7 | 2008 | 570 | 0.120 |
Why?
|
Neurons | 2 | 2020 | 1345 | 0.110 |
Why?
|
Colforsin | 3 | 1998 | 56 | 0.110 |
Why?
|
Myosin Light Chains | 1 | 2013 | 35 | 0.110 |
Why?
|
Patient Discharge | 1 | 2019 | 842 | 0.110 |
Why?
|
Leukocyte Count | 4 | 1997 | 309 | 0.110 |
Why?
|
Infusions, Intravenous | 4 | 2009 | 396 | 0.110 |
Why?
|
Neutrophil Infiltration | 2 | 2012 | 100 | 0.110 |
Why?
|
Cardiac Myosins | 1 | 2013 | 33 | 0.110 |
Why?
|
Astrocytes | 1 | 2014 | 176 | 0.110 |
Why?
|
Young Adult | 4 | 2022 | 11094 | 0.110 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 121 | 0.110 |
Why?
|
Electric Countershock | 1 | 2013 | 126 | 0.110 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2012 | 25 | 0.110 |
Why?
|
Pulmonary Emphysema | 2 | 2015 | 342 | 0.110 |
Why?
|
Epinephrine | 1 | 1993 | 166 | 0.110 |
Why?
|
Wounds, Penetrating | 1 | 1993 | 79 | 0.110 |
Why?
|
Mice, Knockout | 7 | 2017 | 2737 | 0.110 |
Why?
|
Saline Solution, Hypertonic | 1 | 2012 | 55 | 0.110 |
Why?
|
Periodicals as Topic | 1 | 2015 | 239 | 0.110 |
Why?
|
Adrenergic beta-Agonists | 3 | 1998 | 134 | 0.110 |
Why?
|
Cardiomegaly | 1 | 2013 | 168 | 0.100 |
Why?
|
Reflex, Abnormal | 1 | 1991 | 8 | 0.100 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2022 | 44 | 0.100 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 315 | 0.100 |
Why?
|
Foam Cells | 1 | 2011 | 16 | 0.100 |
Why?
|
ras Proteins | 1 | 2012 | 142 | 0.100 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 573 | 0.100 |
Why?
|
Adolescent | 13 | 2023 | 18948 | 0.100 |
Why?
|
Follow-Up Studies | 6 | 2019 | 4768 | 0.100 |
Why?
|
Aged, 80 and over | 5 | 2021 | 6845 | 0.100 |
Why?
|
Diiodothyronines | 1 | 2011 | 4 | 0.100 |
Why?
|
Deoxycholic Acid | 2 | 2021 | 21 | 0.100 |
Why?
|
Myocardial Infarction | 3 | 2011 | 1134 | 0.100 |
Why?
|
Radiotherapy | 1 | 2012 | 187 | 0.100 |
Why?
|
Myelitis | 1 | 2012 | 87 | 0.100 |
Why?
|
Propionates | 1 | 2011 | 35 | 0.100 |
Why?
|
Macrophages, Peritoneal | 1 | 2011 | 97 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2014 | 401 | 0.100 |
Why?
|
Aorta, Abdominal | 1 | 2011 | 43 | 0.100 |
Why?
|
Bradycardia | 1 | 1991 | 58 | 0.100 |
Why?
|
Transplant Recipients | 2 | 2023 | 149 | 0.100 |
Why?
|
Respiration, Artificial | 1 | 1995 | 596 | 0.100 |
Why?
|
RNA, Messenger | 6 | 2012 | 2720 | 0.100 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 1990 | 0.100 |
Why?
|
Surveys and Questionnaires | 4 | 2020 | 4882 | 0.100 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2022 | 131 | 0.100 |
Why?
|
Aortic Aneurysm | 1 | 1991 | 67 | 0.090 |
Why?
|
Neoplastic Stem Cells | 1 | 2014 | 340 | 0.090 |
Why?
|
Transfusion Reaction | 1 | 2010 | 77 | 0.090 |
Why?
|
Wounds and Injuries | 2 | 2012 | 813 | 0.090 |
Why?
|
Hypotension | 1 | 1991 | 135 | 0.090 |
Why?
|
A549 Cells | 2 | 2020 | 56 | 0.090 |
Why?
|
Enzyme Activation | 2 | 2013 | 864 | 0.090 |
Why?
|
Random Allocation | 3 | 2020 | 360 | 0.090 |
Why?
|
Anemia | 1 | 1991 | 156 | 0.090 |
Why?
|
KATP Channels | 2 | 2021 | 22 | 0.090 |
Why?
|
Incidence | 4 | 2020 | 2527 | 0.090 |
Why?
|
Work | 1 | 2009 | 19 | 0.090 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2009 | 52 | 0.090 |
Why?
|
Acute Lung Injury | 1 | 2012 | 313 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2020 | 1531 | 0.080 |
Why?
|
Surgery, Computer-Assisted | 1 | 2009 | 71 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 646 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2008 | 339 | 0.080 |
Why?
|
Phospholipases A2 | 1 | 2008 | 77 | 0.080 |
Why?
|
Actins | 3 | 2017 | 409 | 0.080 |
Why?
|
Actin Cytoskeleton | 1 | 2009 | 103 | 0.080 |
Why?
|
Hindlimb | 3 | 2015 | 138 | 0.080 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 7 | 0.080 |
Why?
|
Heart Function Tests | 2 | 2010 | 68 | 0.080 |
Why?
|
Body Weight | 1 | 1992 | 958 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2010 | 355 | 0.080 |
Why?
|
Troponin | 1 | 2008 | 51 | 0.080 |
Why?
|
Calcium | 3 | 2022 | 1244 | 0.080 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 1859 | 0.080 |
Why?
|
Heart Failure | 2 | 2019 | 2114 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2012 | 546 | 0.080 |
Why?
|
Gene Expression | 5 | 2013 | 1506 | 0.080 |
Why?
|
HSP72 Heat-Shock Proteins | 1 | 2007 | 29 | 0.080 |
Why?
|
Atherosclerosis | 1 | 2011 | 354 | 0.080 |
Why?
|
Echocardiography | 3 | 2008 | 591 | 0.080 |
Why?
|
Lower Extremity | 1 | 2011 | 345 | 0.080 |
Why?
|
Hemoglobins | 1 | 2009 | 293 | 0.080 |
Why?
|
Cell Adhesion Molecules | 2 | 2021 | 188 | 0.080 |
Why?
|
Shock, Hemorrhagic | 2 | 2012 | 213 | 0.080 |
Why?
|
Radiography | 4 | 1999 | 888 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 2 | 2004 | 80 | 0.070 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2007 | 141 | 0.070 |
Why?
|
MAP Kinase Signaling System | 3 | 2015 | 304 | 0.070 |
Why?
|
Immune Sera | 2 | 1996 | 83 | 0.070 |
Why?
|
Prevalence | 1 | 2013 | 2442 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 884 | 0.070 |
Why?
|
Comorbidity | 3 | 2020 | 1600 | 0.070 |
Why?
|
Adenosine Diphosphate | 2 | 1997 | 89 | 0.070 |
Why?
|
Patient Safety | 2 | 2020 | 302 | 0.070 |
Why?
|
Quality Improvement | 3 | 2019 | 1004 | 0.070 |
Why?
|
Mediastinitis | 1 | 2006 | 3 | 0.070 |
Why?
|
Bacitracin | 1 | 2006 | 7 | 0.070 |
Why?
|
Mice, Inbred BALB C | 4 | 2010 | 1245 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2008 | 320 | 0.070 |
Why?
|
Potassium Chloride | 2 | 1996 | 44 | 0.070 |
Why?
|
Age Factors | 4 | 2020 | 3114 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 2008 | 288 | 0.070 |
Why?
|
Molecular Chaperones | 3 | 2014 | 177 | 0.070 |
Why?
|
RNA, Small Interfering | 3 | 2014 | 581 | 0.070 |
Why?
|
Alprostadil | 2 | 1996 | 32 | 0.070 |
Why?
|
Mice, Nude | 2 | 2020 | 668 | 0.070 |
Why?
|
Anti-Infective Agents, Local | 1 | 2006 | 56 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 432 | 0.070 |
Why?
|
Physician Executives | 1 | 2005 | 37 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2013 | 904 | 0.070 |
Why?
|
Infant | 11 | 2014 | 8523 | 0.070 |
Why?
|
Athetosis | 1 | 2005 | 8 | 0.070 |
Why?
|
Chorea | 1 | 2005 | 12 | 0.070 |
Why?
|
Stents | 2 | 2022 | 491 | 0.060 |
Why?
|
Guanylate Cyclase | 2 | 1995 | 37 | 0.060 |
Why?
|
CD-ROM | 1 | 2004 | 7 | 0.060 |
Why?
|
Hospitals, Veterans | 2 | 2004 | 260 | 0.060 |
Why?
|
Macrophages, Alveolar | 2 | 1998 | 364 | 0.060 |
Why?
|
Transforming Growth Factor beta | 1 | 2007 | 468 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 747 | 0.060 |
Why?
|
Glucose | 2 | 2023 | 968 | 0.060 |
Why?
|
Mice, Mutant Strains | 3 | 2011 | 287 | 0.060 |
Why?
|
Microscopy, Fluorescence | 2 | 2018 | 418 | 0.060 |
Why?
|
Mutation | 2 | 2012 | 3493 | 0.060 |
Why?
|
Brain Death | 1 | 2023 | 29 | 0.060 |
Why?
|
Defibrillators, Implantable | 1 | 2008 | 397 | 0.060 |
Why?
|
Brain-Derived Neurotrophic Factor | 2 | 2014 | 115 | 0.060 |
Why?
|
Kinetics | 2 | 1997 | 1658 | 0.060 |
Why?
|
Jagged-1 Protein | 2 | 2013 | 25 | 0.060 |
Why?
|
Serrate-Jagged Proteins | 2 | 2013 | 30 | 0.060 |
Why?
|
Oxygen Consumption | 3 | 2011 | 613 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 1947 | 0.060 |
Why?
|
Cell Line | 2 | 2020 | 2785 | 0.060 |
Why?
|
Receptors, Interleukin-9 | 1 | 2022 | 5 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 232 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 228 | 0.060 |
Why?
|
Transplantation, Autologous | 1 | 2003 | 189 | 0.060 |
Why?
|
Internet | 2 | 2005 | 686 | 0.050 |
Why?
|
Constriction | 2 | 2013 | 46 | 0.050 |
Why?
|
Anticholesteremic Agents | 1 | 2004 | 136 | 0.050 |
Why?
|
Infarction | 1 | 2022 | 17 | 0.050 |
Why?
|
CD18 Antigens | 1 | 2022 | 37 | 0.050 |
Why?
|
Catheterization, Central Venous | 2 | 1993 | 95 | 0.050 |
Why?
|
Annexin A5 | 1 | 2022 | 25 | 0.050 |
Why?
|
Physician's Role | 1 | 2004 | 207 | 0.050 |
Why?
|
Adenosine Triphosphatases | 1 | 2023 | 160 | 0.050 |
Why?
|
Graft Survival | 2 | 2023 | 500 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2016 | 2784 | 0.050 |
Why?
|
Ionophores | 2 | 1999 | 25 | 0.050 |
Why?
|
omega-N-Methylarginine | 2 | 2000 | 28 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2022 | 114 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 472 | 0.050 |
Why?
|
Subclavian Artery | 2 | 2012 | 31 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2004 | 257 | 0.050 |
Why?
|
Heart Atria | 2 | 1992 | 121 | 0.050 |
Why?
|
Mice, Transgenic | 2 | 2017 | 2079 | 0.050 |
Why?
|
Program Development | 2 | 2014 | 372 | 0.050 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2021 | 44 | 0.050 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 152 | 0.050 |
Why?
|
Death | 1 | 2022 | 108 | 0.050 |
Why?
|
Caspases | 1 | 2022 | 275 | 0.050 |
Why?
|
Inflammasomes | 1 | 2022 | 123 | 0.050 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2013 | 373 | 0.050 |
Why?
|
Caspase 3 | 1 | 2022 | 246 | 0.050 |
Why?
|
Blood Transfusion, Autologous | 1 | 2000 | 22 | 0.050 |
Why?
|
Mice, Inbred NOD | 1 | 2022 | 588 | 0.050 |
Why?
|
Tissue Banks | 1 | 2020 | 20 | 0.050 |
Why?
|
Indole Alkaloids | 1 | 2020 | 12 | 0.050 |
Why?
|
Esophageal Mucosa | 1 | 2020 | 18 | 0.050 |
Why?
|
Patient Compliance | 1 | 2004 | 561 | 0.050 |
Why?
|
Interleukin-11 | 1 | 1999 | 10 | 0.050 |
Why?
|
eIF-2 Kinase | 1 | 2020 | 31 | 0.050 |
Why?
|
Ultrasonography | 2 | 2002 | 740 | 0.050 |
Why?
|
Intermediate Care Facilities | 1 | 2019 | 4 | 0.050 |
Why?
|
Biopsy, Needle | 2 | 2012 | 192 | 0.050 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2020 | 53 | 0.040 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1999 | 68 | 0.040 |
Why?
|
Drug Synergism | 2 | 2018 | 346 | 0.040 |
Why?
|
Carbazoles | 1 | 2020 | 81 | 0.040 |
Why?
|
Blotting, Northern | 1 | 1999 | 199 | 0.040 |
Why?
|
Factor VIII | 1 | 1999 | 56 | 0.040 |
Why?
|
Postoperative Period | 1 | 2000 | 317 | 0.040 |
Why?
|
Child, Preschool | 7 | 2014 | 9755 | 0.040 |
Why?
|
Walk Test | 1 | 2019 | 54 | 0.040 |
Why?
|
Elective Surgical Procedures | 1 | 2000 | 165 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 985 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 2021 | 456 | 0.040 |
Why?
|
Histamine Agonists | 1 | 1998 | 2 | 0.040 |
Why?
|
Cell Adhesion | 1 | 2020 | 454 | 0.040 |
Why?
|
Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 8 | 0.040 |
Why?
|
Blood Circulation | 1 | 1998 | 35 | 0.040 |
Why?
|
Stereoisomerism | 1 | 1999 | 94 | 0.040 |
Why?
|
Operative Time | 1 | 2019 | 117 | 0.040 |
Why?
|
Age Distribution | 1 | 2019 | 376 | 0.040 |
Why?
|
Substance Abuse, Intravenous | 1 | 2019 | 77 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2019 | 151 | 0.040 |
Why?
|
Serum Albumin | 1 | 2019 | 151 | 0.040 |
Why?
|
Early Diagnosis | 1 | 2020 | 242 | 0.040 |
Why?
|
Brachiocephalic Trunk | 1 | 2018 | 11 | 0.040 |
Why?
|
Sex Distribution | 1 | 2019 | 370 | 0.040 |
Why?
|
Axillary Artery | 1 | 2018 | 14 | 0.040 |
Why?
|
Infant, Newborn | 7 | 1998 | 5430 | 0.040 |
Why?
|
Antibodies, Neutralizing | 2 | 2012 | 229 | 0.040 |
Why?
|
Multiple Organ Failure | 1 | 1999 | 166 | 0.040 |
Why?
|
Recovery of Function | 1 | 2002 | 610 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2005 | 547 | 0.040 |
Why?
|
Biopsy | 2 | 2013 | 1090 | 0.040 |
Why?
|
Hypertension | 2 | 2020 | 1245 | 0.040 |
Why?
|
Cromakalim | 1 | 1997 | 7 | 0.040 |
Why?
|
Tolbutamide | 1 | 1997 | 9 | 0.040 |
Why?
|
Sarcopenia | 1 | 2019 | 76 | 0.040 |
Why?
|
Skilled Nursing Facilities | 1 | 2019 | 128 | 0.040 |
Why?
|
Cross Infection | 1 | 2020 | 218 | 0.040 |
Why?
|
Chronic Disease | 2 | 1995 | 1645 | 0.040 |
Why?
|
Occupational Health | 1 | 2020 | 175 | 0.040 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 1997 | 30 | 0.040 |
Why?
|
1-Methyl-3-isobutylxanthine | 1 | 1997 | 25 | 0.040 |
Why?
|
Biomedical Research | 1 | 2004 | 630 | 0.040 |
Why?
|
Receptor, ErbB-2 | 1 | 2020 | 321 | 0.040 |
Why?
|
Glyburide | 1 | 1997 | 43 | 0.040 |
Why?
|
Vasculitis | 1 | 1998 | 75 | 0.040 |
Why?
|
Adenylyl Cyclases | 1 | 1997 | 89 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2011 | 1128 | 0.040 |
Why?
|
Sp7 Transcription Factor | 1 | 2017 | 8 | 0.040 |
Why?
|
Antagomirs | 1 | 2017 | 14 | 0.040 |
Why?
|
Sclerosis | 1 | 2017 | 14 | 0.040 |
Why?
|
Risk | 1 | 2020 | 890 | 0.040 |
Why?
|
Endothelium | 1 | 1998 | 121 | 0.040 |
Why?
|
Collagen Type III | 1 | 2017 | 21 | 0.040 |
Why?
|
Cardiology Service, Hospital | 1 | 1997 | 30 | 0.040 |
Why?
|
Muscle Contraction | 2 | 2000 | 415 | 0.040 |
Why?
|
Poly I-C | 1 | 2017 | 55 | 0.040 |
Why?
|
Survival Analysis | 6 | 1999 | 1325 | 0.040 |
Why?
|
Receptors, Histamine H2 | 1 | 1997 | 10 | 0.040 |
Why?
|
Receptors, Purinergic P2 | 1 | 1997 | 21 | 0.040 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 1997 | 128 | 0.040 |
Why?
|
Electrocardiography | 1 | 2000 | 620 | 0.040 |
Why?
|
Brain | 1 | 2009 | 2540 | 0.040 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 276 | 0.040 |
Why?
|
NFATC Transcription Factors | 1 | 2017 | 83 | 0.040 |
Why?
|
ErbB Receptors | 1 | 2020 | 571 | 0.040 |
Why?
|
Prostaglandin Endoperoxides, Synthetic | 1 | 1996 | 4 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2008 | 1922 | 0.040 |
Why?
|
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1996 | 4 | 0.040 |
Why?
|
Colonic Diseases | 1 | 1996 | 27 | 0.040 |
Why?
|
Thromboxane A2 | 1 | 1996 | 13 | 0.040 |
Why?
|
Receptors, Thromboxane | 1 | 1996 | 6 | 0.040 |
Why?
|
Home Care Services | 1 | 2019 | 226 | 0.040 |
Why?
|
Collagen Type I | 1 | 2017 | 113 | 0.040 |
Why?
|
Intestinal Perforation | 1 | 1996 | 43 | 0.040 |
Why?
|
Injections, Intraperitoneal | 1 | 1996 | 107 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 1999 | 537 | 0.040 |
Why?
|
Receptors, Eicosanoid | 1 | 1996 | 2 | 0.040 |
Why?
|
Membrane Proteins | 2 | 2013 | 1093 | 0.040 |
Why?
|
Ventricular Outflow Obstruction | 1 | 1996 | 38 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2019 | 312 | 0.040 |
Why?
|
Forecasting | 2 | 2014 | 372 | 0.040 |
Why?
|
Child | 9 | 1996 | 19561 | 0.040 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 169 | 0.040 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 1996 | 15 | 0.040 |
Why?
|
Aneurysm, False | 1 | 1996 | 48 | 0.040 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1996 | 31 | 0.040 |
Why?
|
Cattle | 2 | 2010 | 994 | 0.040 |
Why?
|
Atrial Function, Left | 1 | 1996 | 7 | 0.040 |
Why?
|
Neutrophil Activation | 1 | 1996 | 100 | 0.040 |
Why?
|
Monitoring, Intraoperative | 1 | 1996 | 43 | 0.040 |
Why?
|
Administration, Oral | 1 | 2018 | 786 | 0.030 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 1996 | 45 | 0.030 |
Why?
|
Automation | 1 | 2016 | 79 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2017 | 187 | 0.030 |
Why?
|
Drug Combinations | 1 | 1997 | 292 | 0.030 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 1996 | 16 | 0.030 |
Why?
|
Femoral Vein | 1 | 1996 | 29 | 0.030 |
Why?
|
Polytetrafluoroethylene | 1 | 1996 | 26 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 1998 | 243 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 154 | 0.030 |
Why?
|
Clinical Protocols | 1 | 1997 | 248 | 0.030 |
Why?
|
Mice, Inbred Strains | 2 | 2008 | 418 | 0.030 |
Why?
|
Lung Compliance | 1 | 1995 | 50 | 0.030 |
Why?
|
Radiation Exposure | 1 | 2016 | 52 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 1996 | 128 | 0.030 |
Why?
|
Drug Interactions | 1 | 1997 | 356 | 0.030 |
Why?
|
Cardiac Output | 1 | 1996 | 154 | 0.030 |
Why?
|
Preoperative Care | 3 | 1996 | 342 | 0.030 |
Why?
|
Vascular Surgical Procedures | 1 | 2018 | 277 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 1260 | 0.030 |
Why?
|
Cardiac Output, Low | 1 | 1995 | 78 | 0.030 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1995 | 76 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 112 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2017 | 314 | 0.030 |
Why?
|
Rabbits | 1 | 1996 | 808 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2020 | 669 | 0.030 |
Why?
|
Job Description | 1 | 2014 | 12 | 0.030 |
Why?
|
Tensins | 1 | 2014 | 3 | 0.030 |
Why?
|
Aminosalicylic Acids | 1 | 2014 | 7 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2016 | 156 | 0.030 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 16 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2015 | 127 | 0.030 |
Why?
|
Smad3 Protein | 1 | 2014 | 49 | 0.030 |
Why?
|
Amrinone | 1 | 1994 | 1 | 0.030 |
Why?
|
Benzenesulfonates | 1 | 2014 | 23 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 1423 | 0.030 |
Why?
|
Receptors, Prostaglandin E | 1 | 1994 | 7 | 0.030 |
Why?
|
Lactobacillus | 1 | 1994 | 26 | 0.030 |
Why?
|
Medical Staff Privileges | 1 | 2014 | 5 | 0.030 |
Why?
|
Nitroglycerin | 1 | 1994 | 24 | 0.030 |
Why?
|
Vascular Patency | 1 | 1994 | 102 | 0.030 |
Why?
|
Immunization, Passive | 1 | 1994 | 82 | 0.030 |
Why?
|
Locomotion | 1 | 2015 | 84 | 0.030 |
Why?
|
RNA | 1 | 2021 | 854 | 0.030 |
Why?
|
High-Frequency Jet Ventilation | 1 | 1994 | 3 | 0.030 |
Why?
|
Femoral Artery | 1 | 1996 | 182 | 0.030 |
Why?
|
Bronchoalveolar Lavage Fluid | 2 | 2012 | 633 | 0.030 |
Why?
|
Pleural Effusion, Malignant | 1 | 1994 | 16 | 0.030 |
Why?
|
Logistic Models | 1 | 2019 | 1995 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2014 | 97 | 0.030 |
Why?
|
Models, Biological | 1 | 2022 | 1756 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 1995 | 122 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 1996 | 563 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2014 | 173 | 0.030 |
Why?
|
Immunoglobulins | 1 | 1994 | 166 | 0.030 |
Why?
|
Pneumonia | 1 | 1999 | 605 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1998 | 739 | 0.030 |
Why?
|
Policy Making | 1 | 2014 | 91 | 0.030 |
Why?
|
Workload | 1 | 2014 | 132 | 0.030 |
Why?
|
Solubility | 1 | 2014 | 240 | 0.030 |
Why?
|
Sotalol | 1 | 2013 | 5 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 1994 | 144 | 0.030 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1994 | 70 | 0.030 |
Why?
|
Cold Temperature | 1 | 1994 | 136 | 0.030 |
Why?
|
Reference Values | 1 | 1995 | 789 | 0.030 |
Why?
|
Amiodarone | 1 | 2013 | 24 | 0.030 |
Why?
|
Catheters, Indwelling | 1 | 1994 | 82 | 0.030 |
Why?
|
Ligation | 1 | 2013 | 83 | 0.030 |
Why?
|
American Heart Association | 1 | 2015 | 313 | 0.030 |
Why?
|
Disease Progression | 1 | 2020 | 2546 | 0.030 |
Why?
|
Protein Binding | 2 | 2010 | 2010 | 0.030 |
Why?
|
Protein Phosphatase 1 | 1 | 2013 | 34 | 0.030 |
Why?
|
Nerve Degeneration | 1 | 2013 | 45 | 0.030 |
Why?
|
Pneumonia, Bacterial | 1 | 1994 | 113 | 0.030 |
Why?
|
Minocycline | 1 | 2013 | 29 | 0.030 |
Why?
|
Drainage | 1 | 1994 | 165 | 0.030 |
Why?
|
Protein Phosphatase 2 | 1 | 2013 | 42 | 0.030 |
Why?
|
Pulmonary Atelectasis | 1 | 1992 | 14 | 0.030 |
Why?
|
Heart Septum | 1 | 1992 | 28 | 0.030 |
Why?
|
Stroke Volume | 1 | 1996 | 553 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2012 | 56 | 0.030 |
Why?
|
Transposition of Great Vessels | 1 | 1992 | 30 | 0.030 |
Why?
|
Ventricular Function | 1 | 1992 | 61 | 0.030 |
Why?
|
Dipeptides | 1 | 2012 | 50 | 0.030 |
Why?
|
Serine | 1 | 2013 | 142 | 0.030 |
Why?
|
Body Mass Index | 1 | 2020 | 2144 | 0.030 |
Why?
|
Cytomegalovirus Infections | 1 | 1994 | 188 | 0.030 |
Why?
|
Angina, Unstable | 1 | 1992 | 82 | 0.030 |
Why?
|
Bronchi | 1 | 1994 | 253 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2012 | 114 | 0.030 |
Why?
|
Nebulizers and Vaporizers | 1 | 2012 | 78 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 416 | 0.030 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2012 | 75 | 0.030 |
Why?
|
Colorado | 2 | 2019 | 4325 | 0.030 |
Why?
|
Trachea | 1 | 1994 | 238 | 0.030 |
Why?
|
Pravastatin | 1 | 2011 | 33 | 0.030 |
Why?
|
Smoking | 1 | 2019 | 1556 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 167 | 0.030 |
Why?
|
Stromal Cells | 1 | 2012 | 103 | 0.030 |
Why?
|
Atropine | 1 | 1991 | 37 | 0.030 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 1992 | 163 | 0.030 |
Why?
|
Heptanoic Acids | 1 | 2011 | 64 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 243 | 0.030 |
Why?
|
Heart Injuries | 1 | 1991 | 39 | 0.030 |
Why?
|
Software | 1 | 2016 | 631 | 0.030 |
Why?
|
Cryopreservation | 1 | 1992 | 102 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2019 | 2977 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 985 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 294 | 0.020 |
Why?
|
Religion and Medicine | 1 | 1991 | 29 | 0.020 |
Why?
|
Pilot Projects | 1 | 2016 | 1477 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 833 | 0.020 |
Why?
|
Macrophage Activation | 1 | 2012 | 169 | 0.020 |
Why?
|
Culture Media | 1 | 2011 | 165 | 0.020 |
Why?
|
Immunosuppressive Agents | 4 | 1998 | 687 | 0.020 |
Why?
|
Perioperative Period | 1 | 2010 | 50 | 0.020 |
Why?
|
Cardiomyopathies | 1 | 2014 | 308 | 0.020 |
Why?
|
Ischemic Preconditioning, Myocardial | 1 | 2010 | 31 | 0.020 |
Why?
|
Pyrroles | 1 | 2011 | 199 | 0.020 |
Why?
|
Odds Ratio | 1 | 2013 | 1043 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2013 | 697 | 0.020 |
Why?
|
Computer Systems | 1 | 2009 | 48 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 361 | 0.020 |
Why?
|
HLA Antigens | 1 | 1991 | 230 | 0.020 |
Why?
|
Actinin | 1 | 2009 | 14 | 0.020 |
Why?
|
Hyperplasia | 1 | 2010 | 169 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2013 | 446 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2012 | 1234 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2011 | 563 | 0.020 |
Why?
|
Polymerization | 1 | 2009 | 130 | 0.020 |
Why?
|
Program Evaluation | 1 | 2013 | 880 | 0.020 |
Why?
|
Sex Factors | 2 | 2010 | 1860 | 0.020 |
Why?
|
Organ Specificity | 1 | 2009 | 287 | 0.020 |
Why?
|
Ventricular Pressure | 1 | 2008 | 42 | 0.020 |
Why?
|
Suicide | 1 | 2014 | 498 | 0.020 |
Why?
|
Tissue and Organ Harvesting | 1 | 2008 | 68 | 0.020 |
Why?
|
Myocardial Depressant Factor | 1 | 2007 | 3 | 0.020 |
Why?
|
Cell Division | 1 | 2009 | 788 | 0.020 |
Why?
|
Microcirculation | 1 | 2008 | 162 | 0.020 |
Why?
|
Decompression, Surgical | 1 | 2008 | 99 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2010 | 457 | 0.020 |
Why?
|
Probability | 1 | 2008 | 316 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2008 | 164 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2008 | 306 | 0.020 |
Why?
|
Kidney | 1 | 2013 | 1355 | 0.020 |
Why?
|
Ointments | 1 | 2006 | 27 | 0.020 |
Why?
|
Transplantation, Homologous | 2 | 1998 | 413 | 0.020 |
Why?
|
Administration, Topical | 1 | 2006 | 154 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2008 | 832 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2004 | 39 | 0.020 |
Why?
|
Binding Sites | 1 | 2008 | 1247 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 1306 | 0.020 |
Why?
|
Body Temperature | 1 | 2005 | 219 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2010 | 995 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2011 | 1805 | 0.010 |
Why?
|
Rectum | 1 | 2005 | 158 | 0.010 |
Why?
|
Microradiography | 1 | 2003 | 2 | 0.010 |
Why?
|
Pharmacy Service, Hospital | 1 | 2004 | 88 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2005 | 564 | 0.010 |
Why?
|
DNA | 1 | 2010 | 1401 | 0.010 |
Why?
|
Spectrum Analysis | 1 | 2003 | 89 | 0.010 |
Why?
|
Faculty, Medical | 1 | 2005 | 258 | 0.010 |
Why?
|
Rupture | 2 | 1994 | 107 | 0.010 |
Why?
|
Mentors | 1 | 2004 | 170 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 4734 | 0.010 |
Why?
|
Drug Prescriptions | 1 | 2004 | 271 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2011 | 1556 | 0.010 |
Why?
|
United States Department of Veterans Affairs | 1 | 2004 | 564 | 0.010 |
Why?
|
Guanidines | 1 | 2000 | 38 | 0.010 |
Why?
|
Bone and Bones | 1 | 2003 | 296 | 0.010 |
Why?
|
Tumor Necrosis Factor Decoy Receptors | 1 | 1999 | 8 | 0.010 |
Why?
|
Cytokine Receptor gp130 | 1 | 1999 | 11 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2000 | 171 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1999 | 162 | 0.010 |
Why?
|
Pancreatic Elastase | 1 | 1999 | 74 | 0.010 |
Why?
|
Platelet Activating Factor | 1 | 1999 | 95 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2000 | 339 | 0.010 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 1999 | 148 | 0.010 |
Why?
|
NADPH Oxidases | 1 | 1999 | 141 | 0.010 |
Why?
|
Dimercaprol | 1 | 1998 | 7 | 0.010 |
Why?
|
Penicillamine | 1 | 1998 | 24 | 0.010 |
Why?
|
Cost Control | 1 | 1998 | 46 | 0.010 |
Why?
|
Methicillin Resistance | 1 | 1998 | 19 | 0.010 |
Why?
|
Plasmapheresis | 1 | 1998 | 24 | 0.010 |
Why?
|
Hemoptysis | 1 | 1998 | 32 | 0.010 |
Why?
|
Bronchiolitis Obliterans | 1 | 1998 | 69 | 0.010 |
Why?
|
Capillaries | 1 | 1998 | 107 | 0.010 |
Why?
|
Teaching | 1 | 2000 | 241 | 0.010 |
Why?
|
Heart-Lung Transplantation | 1 | 1997 | 11 | 0.010 |
Why?
|
Isothiuronium | 1 | 1997 | 4 | 0.010 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 1998 | 89 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1998 | 299 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 1999 | 462 | 0.010 |
Why?
|
Palliative Care | 2 | 1994 | 632 | 0.010 |
Why?
|
Diverticulitis, Colonic | 1 | 1996 | 8 | 0.010 |
Why?
|
Antigens, CD | 1 | 1999 | 506 | 0.010 |
Why?
|
Creatine Kinase | 1 | 1996 | 76 | 0.010 |
Why?
|
Myocardial Reperfusion | 1 | 1996 | 62 | 0.010 |
Why?
|
Diastole | 1 | 1996 | 147 | 0.010 |
Why?
|
Milrinone | 1 | 1995 | 27 | 0.010 |
Why?
|
Pulmonary Alveoli | 1 | 1998 | 395 | 0.010 |
Why?
|
Edema, Cardiac | 1 | 1994 | 4 | 0.010 |
Why?
|
Recurrence | 1 | 1998 | 998 | 0.010 |
Why?
|
Cardiotonic Agents | 1 | 1995 | 133 | 0.010 |
Why?
|
Ganciclovir | 1 | 1994 | 46 | 0.010 |
Why?
|
Dexamethasone | 1 | 1997 | 323 | 0.010 |
Why?
|
Pyridones | 1 | 1995 | 120 | 0.010 |
Why?
|
Opportunistic Infections | 1 | 1994 | 45 | 0.010 |
Why?
|
Lung Diseases, Obstructive | 1 | 1994 | 54 | 0.010 |
Why?
|
Anesthesia, Local | 1 | 1994 | 17 | 0.010 |
Why?
|
Acyclovir | 1 | 1994 | 104 | 0.010 |
Why?
|
Contusions | 1 | 1994 | 21 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 1996 | 757 | 0.010 |
Why?
|
Viremia | 1 | 1994 | 133 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 1998 | 348 | 0.010 |
Why?
|
Contraindications | 1 | 1993 | 102 | 0.010 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1994 | 130 | 0.010 |
Why?
|
Hemorrhage | 1 | 1998 | 663 | 0.010 |
Why?
|
H-Y Antigen | 1 | 1993 | 9 | 0.010 |
Why?
|
Histocompatibility | 1 | 1993 | 27 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 2500 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 1994 | 205 | 0.010 |
Why?
|
Methods | 1 | 1992 | 67 | 0.010 |
Why?
|
Sputum | 1 | 1994 | 293 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 1995 | 1174 | 0.010 |
Why?
|
Polyethylene Terephthalates | 1 | 1991 | 15 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1994 | 551 | 0.010 |
Why?
|
Blood Volume | 1 | 1991 | 60 | 0.010 |
Why?
|
Suture Techniques | 1 | 1991 | 135 | 0.010 |
Why?
|
Cardiac Pacing, Artificial | 1 | 1991 | 90 | 0.010 |
Why?
|
Coronary Angiography | 1 | 1992 | 336 | 0.010 |
Why?
|
Oxidative Stress | 1 | 1996 | 1204 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 1998 | 985 | 0.010 |
Why?
|
Communicable Diseases | 1 | 1991 | 135 | 0.010 |
Why?
|
Cystic Fibrosis | 1 | 1998 | 1003 | 0.010 |
Why?
|
Regression Analysis | 1 | 1991 | 1018 | 0.000 |
Why?
|
Anti-Bacterial Agents | 1 | 1994 | 1562 | 0.000 |
Why?
|